MediWound
42 Ha'Yarkon Street
Yavne
Tel: 972-8-9324010
Fax: 972-8-9324011
184 articles about MediWound
-
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
3/14/2024
MediWound Ltd. today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, March 21, 2024.
-
MediWound to Participate in Two Upcoming Investor Conferences
2/5/2024
MediWound Ltd. today announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference, taking place virtually on February 13-14, 2024, as well as the upcoming TD Cowen 44th Annual Health Care Conference, taking place in Boston on March 4-6, 2024.
-
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
1/9/2024
MediWound Ltd. today announced that the U.S. Food and Drug Administration (FDA) has completed their filing review and accepted a supplement to the NexoBrid® biologics license application (sBLA) for the removal of eschar in pediatric patients with deep partial- and/or full-thickness thermal burns.
-
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
12/28/2023
MediWound Ltd. announced that the U.S. Department of Defense, through the Medical Technology Enterprise Consortium, has awarded MediWound an additional $6.7 million in non-dilutive funding to develop NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army.
-
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
12/21/2023
MediWound Ltd. announced the publication of a peer-reviewed paper, titled “An Open-label, Proof of Concept Study, Assessing the Effects of Bromelain-Based Enzymatic Debridement on Biofilm and Microbial Loads in Patients with Venous Leg and Diabetic Foot Ulcers” in the December 2023 issue of WOUNDS Journal.
-
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
11/21/2023
MediWound Ltd., the global leader in next-generation enzymatic therapeutics for tissue repair, announced financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
11/21/2023
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023.
-
MediWound Announces Collaboration with 3M on EscharEx® Phase III StudyMediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers
10/11/2023
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced collaboration with 3M Health Care.
-
MediWound Deploys NexoBrid® for Emergency Supply
10/9/2023
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in Israel.
-
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. ArmyR&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution
9/26/2023
MediWound Ltd. announced that the U.S. Department of Defense, through the Medical Technology Enterprise Consortium, has awarded MediWound additional funding to develop NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army.
-
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
9/21/2023
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced the U.S. commercial availability of NexoBrid® for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns.
-
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
9/11/2023
MediWound Ltd. announced its successful participation at the recently concluded 20th European Burns Association Congress held in Nantes, France on September 6-9, 2023.
-
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced its participation in the upcoming H.C. Wainwright 25th Annual Global Investment Conference.
-
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
8/15/2023
MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study of EscharEx® in venous leg ulcers.
-
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
8/15/2023
MediWound Ltd. announced it has entered into a research collaboration agreement with MIMEDX Group, Inc. MIMEDX will provide its market leading placental tissue allograft EPIFIX® to be used during the wound healing phase of the EscharEx® Phase III study in venous leg ulcers.
-
MediWound to Report Second Quarter 2023 Financial Results
8/7/2023
MediWound Ltd. today announced that the Company will release its financial results for the second quarter ended June 30, 2023 on Tuesday, August 15, 2023.
-
MediWound Announces Commercial Launch of NexoBrid® in JapanKaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement
8/1/2023
MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced that its strategic partner, Kaken Pharmaceutical Co. Ltd, launched NexoBrid® in Japan for the treatment of deep partial thickness and full thickness burns in adults and pediatric patients.
-
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
7/10/2023
MediWound Ltd. today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma (BCC).
-
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
6/14/2023
MediWound Ltd. announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by Maxim Group LLC and hosted by M-Vest.
-
MediWound to Report First Quarter 2023 Financial Results Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time
5/12/2023
MediWound Ltd., the global leader in next-generation enzymatic therapeutics for tissue repair, announced that the Company will release its financial results for the first quarter ended March 31, 2023 on Tuesday, May 30, 2023.